The Department of Radiation Oncology enrolls as many as 200 new patients each year in clinical trials. Faculty members hold leadership positions in the Radiation Therapy Oncology Group (RTOG), which develops and oversees all national radiation oncology trials funded by the National Cancer Institute.
See current clinical trial information below or contact the Clinical Research office at 214-645-7322.
STU 052018.052 (GammaPod Boost) Tumor Bed Boost Using a Breast-Specific Radiosurgery Device, the GammaPod: Registry Study and Evaluation of Quality of Life with Development of Sizing Nomogram. Learn about the GammaPod.
STU 2018.0236 (Tailor RT) A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node-Positive Breast Cancer.
STU 2019.1099 Single Institution Pilot Study to Detect Radiation-Induced Cardiotoxicity in Left-Sided Breast Cancer Patients Using Hyperpolarized Carbon 13-Based Magnetic Resonance Spectroscopic Imaging.
STU 2019.1183 A Phase I Dose-Escalation Study of Single Fraction Pre-Operative Partial Breast (S-PBI) for Early Stage Breast Cancer.
Central Nervous System
STU 122016.064 (Neurocog. Decline) Phase I/II Trial to Determine the Neurocognitive Decline in Patients with Multiple (>6) Brain Metastases Treated with Distributed Stereotactic Radiosurgery.
STU 022015.106 (SRS-Dose Escalation) A Phase I Dose-Escalation Study of Stereotactic Radiosurgery for Brain Metastasis without Whole Brain Radiation.
STU 2019.1492 (INNATE) Immunotherapy During Neoadjuvant Therapy for Rectal Cancer, a Phase II Randomized Multicenter Trial with and without APX005M, an Anti-CD40 Agonist.
STU 2020.0166 (EA2182) A Randomized Phase II Study of Deintensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma.
STU 2020.1216 (GRECO-2) A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in Combination with GC4711 in the Treatment of Locally Advanced or Borderline Resectable, Non-Metastatic Pancreatic Cancer.
STU 2020.1394 Phase I Trial of Ultra-Fractionated Adaptive Radiotherapy, Chemotherapy and Selective Omission of Surgery for Locally Advanced Rectal Cancer.
STU 022017.032 (NRG-GU002) Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel.
STU 122016.067 (Salvenza) Phase II Randomized Placebo-Controlled Double-Blinded Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy (SALV-ENZA).
STU 022015.058 (IVC Thrombus) Safety Lead-In Phase II Trial of Neo-Adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC.
STU 092017.018 (POTEN-C) Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C): A Phase II Randomized Controlled Trial of Stereotactic Ablative Body Radiotherapy (SAbR) with or without Neurovascular Sparing for Erectile Function Preservation in Localized Prostate Cancer. Learn more about the POTEN-C trial.
STU 2019.1065 (STEEL) A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features.
STU 2019.1596 (F-SHARP) A Phase I/II Trial of Focal Salvage High-Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated with Prior Radiotherapy.
STU 2020.0329 (RAVENS) A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
STU 022011.213 (ASCLEPIuS) A Multi-Center Study of Androgen Suppression with Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS). A Phase 1/2 Trial in High-Risk or Node-Positive Prostate Cancer.
STU 2021.1091 (NRG-GU010) Parallel Phase III Randomized Trial of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensificiation and Intensification Clinical Trial Evaluation (GUIDANCE).
STU 2021.0787 A Safety Lead-in Single Arm Phase II Study for Image-Guided Ultrafractionated Radiation Therapy for Treatment of Metastatic Cervical Cancer.
STU 2021.0852 Daily Adaptive External Beam Radiation Therapy in the Treatment of Carcinoma of the Cervix: A Phase II Trial of an Individualized Approach for Intestinal Toxicity Reduction (ARTIA-Cervix).
Head and Neck
STU 072014.041 (NRG-HN001) Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA).
STU 2019.1316 (KEYSTROKE) A Randomized Phase II Study of Pembrolizumab (KEYTRUDA) Plus Stereotactic Re-Irradiation versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma.
STU 2020.0522 (HYPORT-HN) A Randomized Non-Inferiority Phase II Study of Hypofractionated Post-Operative Radiation Therapy for Head and Neck Squamous Cell Carcinoma.
STU 2020.1079 (HYHOPE) Phase I Study of De-Intensified Hypofractionated Radiation Therapy for Human Papilloma Virus-Associated Oropharynx Cancer.
STU 2020.1000 (EA3161) A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV-Positive OPCA.
STU 022013.055 (RTOG 1216) Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck.
STU 2021.041 (DARTBOARD) A Prospective Randomized Phase II Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer.
STU 2021.0529 Registry Study to Evaluate the Clinical and Dosimetric Outcomes of Cancer Patients Adaptive Radiation Therapy (ART).
STU 042017.024 (NRG-LU002) Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Cancer (NSCLC): A Randomized Phase II/III Trial. Learn more about the NRG trial.
STU 022015.069 (JoLT-Ca/STABLEMATES) A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC), the STABLEMATES Trial. Learn more about the JoLT-CA/STABLEMATES trial.
STU 2019.0858 (PACIFIC 4/RTOG-3515) A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-Small Cell Lung Cancer.
STU 2019.1764 Phase I/II Study of Stereotactic Body Radiation Therapy (SBRT) with or without GC4711 for Early Stage, Centrally Located or Large Non-Small Cell Lung Cancer (NSCLC).
STU 2021.0475 Pilot Study of Ruxolitinib in the Treatment of Cancer Cachexia.
STU 062016.073 (Lung SAbR) Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereotactic Ablative Body Radiotherapy (SAbR).
STU 2019.1390 Tissue Procurement and Outcome Collection for Cancer Patients With and Without Cachexia.
STU 2020.1106 A Phase I/II Trial of ‘Re-Priming’ Stereotactic Ablative Radiotherapy (SAbR) for Relapsed/Refractory Non-Hodgkin Lymphoma Patients in Incomplete Response after Chimeric Antigen Receptor T-cell (CAR-T) Salvage Therapy.
STU 2019.1142 Video-Based Motion Detection and Prediction for Pediatric Radiotherapy.
STU 072010.098 Tissue Procurement and Outcome Collection for Radiotherapy-Treated Patients.
STU 2021.0206 Volunteer Scanning for Testing, Evaluating, and Enhancing 1.5T MRI Systems Dedicated to Radiation Treatment Planning and MRI-Guided Radiation Therapy.
STU 2021.0976 Prospective Data Registry and Quality-of-Life Assessment of Patients Undergoing Radiotherapy with the RefleXion Medical Radiotherapy System (PREMIER).